Literature DB >> 30920297

Multitranscriptome analyses reveal prioritized genes specifically associated with liver fibrosis progression independent of etiology.

Wei Chen1,2, Xiaoning Wu3, Xuzhen Yan3, Anjian Xu1,2, Aiting Yang1,2, Hong You1,2,3.   

Abstract

Elimination or suppression of causative factors can raise the possibility of liver fibrosis regression. However, different injurious stimuli will give fibrosis from somewhat different etiologies, which, in turn, may hamper the discovery of liver fibrosis-specific therapeutic drugs. Therefore, the analogical cellular and molecular events shared by various etiology-evoked liver fibrosis should be clarified. Our present study systematically integrated five publicly available transcriptomic data sets regarding liver fibrosis with different etiologies from the Gene Expression Omnibus database and performed a series of bioinformatics analyses and experimental verifications. A total of 111 significantly upregulated and 16 downregulated genes were identified specific to liver fibrosis independent of any etiology. These genes were predominately enriched in some Kyoto Encyclopedia of Genes and Genomes pathways, including the "PI3K-AKT signaling pathway," "Focal adhesion," and "ECM-receptor interaction." Subsequently, five prioritized liver fibrosis-specific genes, including COL4A2, THBS2, ITGAV, LAMB1, and PDGFRA, were screened. These genes were positively associated with each other and liver fibrosis progression. In addition, they could robustly separate all stages of samples in both training and validation data sets with diverse etiologies when they were regarded as observed variables applied to principal component analysis plots. Expressions of all five genes were confirmed in activated primary mouse hepatic stellate cells (HSCs) and transforming growth factor β1-treated LX-2 cells. Moreover, THBS2 protein was enhanced in liver fibrosis rodent models, which could promote HSC activation and proliferation and facilitate NOTCH1/JAG1 expression in HSCs. Overall, our current study may provide potential targets for liver fibrosis therapy and aid to a deeper understanding of the molecular underpinnings of liver fibrosis. NEW & NOTEWORTHY Prioritized liver fibrosis-specific genes THBS2, COL4A2, ITGAV, LAMB1, and PDGFRA were identified and significantly associated with liver fibrosis progression and could be combined to discriminate liver fibrosis stages regardless of any etiology. Among the identified prioritized liver fibrosis-specific targets, THBS2 protein was confirmed to be enhanced in liver fibrosis rodent models, which could promote hepatic stellate cell (HSC) activation and proliferation and facilitate NOTCH1/JAG1 expression in HSCs.

Entities:  

Keywords:  THBS2; etiology; hub genes; liver fibrosis; progression; transcriptome

Mesh:

Substances:

Year:  2019        PMID: 30920297     DOI: 10.1152/ajpgi.00339.2018

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  7 in total

Review 1.  Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease.

Authors:  Philippe Lefebvre; Bart Staels
Journal:  Nat Rev Endocrinol       Date:  2021-08-20       Impact factor: 43.330

2.  3D-printed dermis-specific extracellular matrix mitigates scar contraction via inducing early angiogenesis and macrophage M2 polarization.

Authors:  Lei Chen; Zhiyong Li; Yongtai Zheng; Fei Zhou; Jingling Zhao; Qiyi Zhai; Zhaoqiang Zhang; Tianrun Liu; Yongming Chen; Shaohai Qi
Journal:  Bioact Mater       Date:  2021-09-22

3.  Single-cell transcriptomic analysis reveals a novel cell state and switching genes during hepatic stellate cell activation in vitro.

Authors:  Hua Wang; Shaoping Zheng; Hongbo Jiang; Xuejia Wang; Fengqin Zhou; Zhihong Weng
Journal:  J Transl Med       Date:  2022-01-29       Impact factor: 5.531

4.  Distinct Adipogenic and Fibrogenic Differentiation Capacities of Mesenchymal Stromal Cells from Pancreas and White Adipose Tissue.

Authors:  Heja Aga; George Soultoukis; Mandy Stadion; Francisco Garcia-Carrizo; Markus Jähnert; Pascal Gottmann; Heike Vogel; Tim J Schulz; Annette Schürmann
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

5.  Expression of Fibrosis-Related Genes in Liver and Kidney Fibrosis in Comparison to Inflammatory Bowel Diseases.

Authors:  Miha Jerala; Nina Hauptman; Nika Kojc; Nina Zidar
Journal:  Cells       Date:  2022-01-18       Impact factor: 6.600

6.  Genome-wide CRISPR Screening to Identify Drivers of TGF-β-Induced Liver Fibrosis in Human Hepatic Stellate Cells.

Authors:  Shan Yu; Matthew Ericson; Andrea Fanjul; Derek M Erion; Maria Paraskevopoulou; Erin N Smith; Banumathi Cole; Ryan Feaver; Corine Holub; Narender Gavva; Shane R Horman; Jie Huang
Journal:  ACS Chem Biol       Date:  2022-03-11       Impact factor: 4.634

7.  Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.

Authors:  Kazuhiro Kozumi; Takahiro Kodama; Hiroki Murai; Sadatsugu Sakane; Olivier Govaere; Simon Cockell; Daisuke Motooka; Naruyasu Kakita; Yukinori Yamada; Yasuteru Kondo; Yuki Tahata; Ryoko Yamada; Hayato Hikita; Ryotaro Sakamori; Yoshihiro Kamada; Ann K Daly; Quentin M Anstee; Tomohide Tatsumi; Eiichi Morii; Tetsuo Takehara
Journal:  Hepatology       Date:  2021-08-21       Impact factor: 17.425

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.